Yıl: 2011 Cilt: 45 Sayı: 3 Sayfa Aralığı: 565 - 576 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Staphylococcus aureus ve antibiyotik direnci

Öz:
Metisiline dirençli Staphylococcus aureus (MRSA), ilk kez 1961 yılında tanımlandıktan sonra tüm dünyada önemli bir problem haline gelmiştir. Son yıllarda MRSA izolatları hem hastane kaynaklı hem de toplum kaynaklı enfeksiyonlara yol açmaktadır. MRSA enfeksiyonlarının tedavisinde halen vankomisin ve teikoplanin olmak üzere glikopeptid grubu antibiyotikler kullanılmaktadır. Son 10 yıldır MRSA ile meydana gelen enfeksiyonların epidemiyolojisinde önemli değişiklikler meydana gelmiştir. Gerek vankomisine dirençli gerekse vankomisine azalmış duyarlılık gösteren izolatlar bir tehdit oluşturmaktadır. Yakın zamanda kunipristin/dalfopristin, linezolid, tigesiklin ve daptomisin gibi yeni ilaçlar MRSA enfeksiyonlarının tedavisinde kullanılmaya başlanmıştır. Ancak bu ilaçların sadece belirli endikasyonlarda kullanım onayı vardır ve klinik kullanıma yeni girmelerine rağmen bu ilaçlara karşı da direnç görülmeye başlanmıştır. Bu derleme yazıda, MRSA enfeksiyonlarının tedavisinde kullanılan yeni ilaçlar ve bu ilaçlara karşı direnç mekanizmaları tartışılmıştır.
Anahtar Kelime:

Konular: Mikrobiyoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Farmakoloji ve Eczacılık

Staphylococcus aureus and antibiotic resistance

Öz:
After the report of first case of methicillin-resistant Staphylococcus aureus (MRSA) in 1961, MRSA become a major problem worldwide. Over the last decade MRSA strains have emerged as serious pathogens in nosocomial and community settings. Glycopeptides (vancomycin and teicoplanin) are still the current mainstay of therapy for infections caused by MRSA. In the last decade dramatic changes have occurred in the epidemiology of MRSA infections. The isolates with reduced susceptibility and in vitro resistance to vancomycin have emerged. Recently, therapeutic alternatives such as quinupristin/ dalfopristin, linezolid, tigecycline and daptomycin have been introduced into clinical practice for treating MRSA infections. Nevertheless, these drugs are only approved for certain indication and resistance has already been reported. In this review, the new information on novel drugs for treating MRSA infections and the resistance mechanisms of these drugs were discussed.
Anahtar Kelime:

Konular: Mikrobiyoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Farmakoloji ve Eczacılık
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik
  • 1. Culos KA, Cannon JP, Grim SA. Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Am J Ther 2011 [Epub ahead of print] PubMed PMID: 21642833.
  • 2. Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP. Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 2010; 14(Suppl 4): S7-11.
  • 3. Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009; 15(5): 403-12.
  • 4. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46(2): 193-200.
  • 5. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13(3): 222-35.
  • 6. Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis 2010; 14(Suppl 4): S19-22.
  • 7. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358(9277): 207-8.
  • 8. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40(7): 1058-60.
  • 9. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13(3): 222-35.
  • 10. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol 2008; 8(6): 747-63.
  • 11. International Working Group on the Classification of Staphylococcal Cassette Chromosome (SCC) Elements (IWG-SCC). www.sccmec.org
  • 12. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008; 27(1): 3-15.
  • 13. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62(Suppl 1): i1-9.
  • 14. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45(Suppl 3): S171-6.
  • 15. Rehm SJ, Tice A. Staphylococcus aureus: methicillin-susceptible S.aureus to methicillin-resistant S.aureus and vancomycin-resistant S.aureus. Clin Infect Dis 2010; 51(Suppl 2): S176-82.
  • 16. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40(1): 135-6.
  • 17. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340(7): 493-501.
  • 18. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351(9110): 1212.
  • 19. Hanaki H, Hososaka Y, Yanagisawa C, et al. Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan. J Infect Chemother 2007; 13(2): 118-21.
  • 20. de Lassence A, Hidri N, Timsit JF, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006; 42(2): 170-8.
  • 21. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23(1): 99- 139.
  • 22. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin- intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55(1): 405-10.
  • 23. Bell JM, Walters JD, Turnidge JD, Jones RN. hVISAs are common among vancomycin susceptible methicillin- resistant Staphylococcus aureus (MRSA): Report from SENTRY Asia-Pacific region. In: Program and Abstracts of the 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006, San Francisco. Washington DC: American Society for Microbiology; Abstract C2-1160.
  • 24. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hasçelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56(3): 519-23.
  • 25. Gould IM. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011; 66(Suppl 4): iv17-21.
  • 26. McAleese F, Wu SW, Sieradzki K, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol 2006; 188(3): 1120-33.
  • 27. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010; 10(5): 516-21.
  • 28. Cui L, Iwamoto A, Lian JQ, et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50(2): 428-38.
  • 29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement, Document M100-S20, 2010. CLSI Wayne, PA.
  • 30. Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39(7): 2439-44.
  • 31. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9(10): 617-24.
  • 32. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37(3): 219-24.
  • 33. Moreillon P. New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect 2008; 14(Suppl 3): 32-41.
  • 34. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009; 23(1): 99-131.
  • 35. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007; 59(3): 309-17.
  • 36. Luh KT, Hsueh PR, Teng LJ, et al. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44(12): 3374-80.
  • 37. Dogruman-Al F, Akça G, Aykan B, Sipahi AB, Çağlar K. Metisiline dirençli Staphylococcus aureus suşlarında kinupristin/dalfopristin, linezolid duyarlılıkları ve makrolit-linkozamit-streptogramin B direnci. İnfeksiyon Derg 2008; 22(3): 153-63.
  • 38. Öksüz L, Gürler N. Klinik örneklerden izole edilen metisiline dirençli stafilokok suşlarının son yıllarda kullanıma giren antibiyotiklere in vitro duyarlılığı. ANKEM 2009; 23(2): 71-7.
  • 39. Efe S, Sinirtas M, Ozakin C. In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains. Mikrobiyol Bul 2009; 43(4): 639-43.
  • 40. Adaleti R, Nakipoglu Y, Ceran N, Tasdemir C, Kaya F, Tasdemir S. Prevalence of phenotypic resistance of Staphylococcus aureus isolates to macrolide, lincosamide, streptogramin B, ketolid and linezolid antibiotics in Turkey. Braz J Infect Dis 2010; 14(1): 11-4.
  • 41. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010; 65(11): 2329-35.
  • 42. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303(22): 2260-4.
  • 43. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 2011; 37(3): 202-9.
  • 44. Sancak B, Yagci S, Mirza HC, Hascelik G. Evaluation of vancomycin and daptomycin MIC trends against methicillin resistant Staphylococcus aureus blood isolates collected in Hacettepe Hospital from 1999 to 2009. 111th General Meeting of American Society for Microbiology. May 21-24, 2011, New Orleans, Louisiana. Abst. No. C-100.
  • 45. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 2010; 54(8): 3079-85.
  • 46. Florescu I, Beuran M, Dimov R, et al; 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62(Suppl 1): i17-28.
  • 47. Shams W, Walker ES, Levy F, Reynolds SA, Peterson SM, Sarubbi FA. Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006. Chemotherapy 2010; 56(5): 411-6.
  • 48. Zhanel GG, DeCorby M, Adam H, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010; 54(11): 4684-93.
  • 49. Akoğlu H, Zarakolu P, Altun B, Unal S. Hacettepe Üniversitesi Erişkin Hastanesinde 2004-2005 yıllarında izole edilen hastane kaynaklı metisilin dirençli Staphylococcus aureus suşlarının epidemiyolojik ve moleküler özellikleri. Mikrobiyol Bul 2010; 44(3): 343-55.
  • 50. Ünlü M, Vardar G, Yağmuroğlu A, Yıldırım D. Klinik örneklerden soyutlanan Staphylococcus aureus suşlarına tigesiklin etkinliği. ANKEM 2009; 23(1): 13-6.
  • 51. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm
APA SANCAK B (2011). Staphylococcus aureus ve antibiyotik direnci. , 565 - 576.
Chicago SANCAK Banu Staphylococcus aureus ve antibiyotik direnci. (2011): 565 - 576.
MLA SANCAK Banu Staphylococcus aureus ve antibiyotik direnci. , 2011, ss.565 - 576.
AMA SANCAK B Staphylococcus aureus ve antibiyotik direnci. . 2011; 565 - 576.
Vancouver SANCAK B Staphylococcus aureus ve antibiyotik direnci. . 2011; 565 - 576.
IEEE SANCAK B "Staphylococcus aureus ve antibiyotik direnci." , ss.565 - 576, 2011.
ISNAD SANCAK, Banu. "Staphylococcus aureus ve antibiyotik direnci". (2011), 565-576.
APA SANCAK B (2011). Staphylococcus aureus ve antibiyotik direnci. Mikrobiyoloji Bülteni, 45(3), 565 - 576.
Chicago SANCAK Banu Staphylococcus aureus ve antibiyotik direnci. Mikrobiyoloji Bülteni 45, no.3 (2011): 565 - 576.
MLA SANCAK Banu Staphylococcus aureus ve antibiyotik direnci. Mikrobiyoloji Bülteni, vol.45, no.3, 2011, ss.565 - 576.
AMA SANCAK B Staphylococcus aureus ve antibiyotik direnci. Mikrobiyoloji Bülteni. 2011; 45(3): 565 - 576.
Vancouver SANCAK B Staphylococcus aureus ve antibiyotik direnci. Mikrobiyoloji Bülteni. 2011; 45(3): 565 - 576.
IEEE SANCAK B "Staphylococcus aureus ve antibiyotik direnci." Mikrobiyoloji Bülteni, 45, ss.565 - 576, 2011.
ISNAD SANCAK, Banu. "Staphylococcus aureus ve antibiyotik direnci". Mikrobiyoloji Bülteni 45/3 (2011), 565-576.